Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Àü¸³¼±ºñ´ëÁõȯÀÚ¿¡¼­ Àü¸³¼±ÀÇ Á¶Á÷À¯Çü¿¡ µû¸¥ Alpha1-¼ö¿ëüÂ÷´ÜÁ¦ÀÇ Ä¡·áÈ¿°ú The Effect of Alpha1-blockers according to Histological Compositions in Patients with Benign Prostatic Hyperplasia

´ëÇѺñ´¢±â°úÇÐȸÁö 1998³â 39±Ç 8È£ p.783 ~ 788
°­Èï¿ø, ¹ÚöÈñ, ÀÌÁ¤È£, Á¶½ÂÁ¦,
¼Ò¼Ó »ó¼¼Á¤º¸
°­Èï¿ø (  ) 
°è¸í´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

¹ÚöÈñ (  ) 
°è¸í´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç
ÀÌÁ¤È£ (  ) 
°è¸í´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç
Á¶½ÂÁ¦ (  ) 
°è¸í´ëÇб³ ÀÇ°ú´ëÇÐ Çغκ´¸®Çб³½Ç

Abstract

¼­·Ð
Àü¸³¼±ºñ´ëÁõÀº Àü¸³¼±ÀÇ °£Áú(stroma)°ú ¼±(glandular) Á¶Á÷ÀÇ Áõ½Ä°úÁ¤ÀÌ´Ù. Àü¸³¼±ºñ´ë
ÁõÀ» °¡Áø ȯÀÚ¿¡ ÀÓ»óÁõ»óÀº ¹æ±¤ÇϺÎÆó»ö¿¡ ±âÀÎÇϸç, ¿©±â¿¡´Â µÎ°¡Áö ±âÀüÀÌ °ü¿©µÈ´Ù.
¸ÕÀú, ¹æ±¤ÇϺθ¦ µÑ·¯½Î°í ÀÖ´Â °úÁõ½ÄµÈ Àü¸³¼±Á¶Á÷ ÀÚü¿¡ ±âÀÎÇÏ´Â ÇغÎÇÐÀû ¶Ç´Â Á¤Àû
(static) ¿ä¼Ò¿Í µÑ°·Î, Àü¸³¼±¿¡ ÀÖ´Â ÆòÈ°±ÙÀÇ ±äÀåµµ¿Í °ü·ÃµÈ µ¿Àû(dynamic) ¿ä¼Ò°¡ °ü
¿©ÇÑ´Ù.
1976³â¿¡ CameµîÀÌ Àü¸³¼±ºñ´ëÁõ¿¡¼­ ºñ¼±ÅÃÀû ¥á-¼ö¿ëüÂ÷´ÜÁ¦ÀÎ phenoxybenzamineÀÌ
È¿°ú°¡ ÀÖ´Ù°í º¸°íÇÑ ÀÌ·¡·Î ¿©·¯ ¿¬±¸¿¡ ÀÇÇØ Àü¸³¼±ÀÇ ÆòÈ°±Ù±äÀåµµ´Â ¥á
1-¼ö¿ëü¿¡ ÀÇÇØ ¸Å°³µÇ´Â °ÍÀÌ ¹àÇôÁö°Ô µÇ¾ú´Ù. ÇöÀç´Â Àå±âÁö¼ÓÇüÀÇ ¼±ÅÃ
Àû ¥á1-¼ö¿ëüÂ÷´ÜÁ¦°¡ ³Î¸® ¾²ÀÌ°í ÀÖ´Ù. ÀÌ ¾à¹°µéÀº Àü¸³¼±³» °£ÁúºÎÀ§ÀÇ
ÆòÈ°±Ù¼öÃàÀ» ¾ïÁ¦ÇÏ´Â ÀÛ¿ëÀ» ÇÏ¿© ¹æ±¤ÃⱸÆó¼â¾ÐÀ» ³·Ãß°í ±× °á°ú ¹è´¢Áõ»óÀ» È£Àü½ÃŲ
´Ù. ±×·¯³ª ¼±Á¶Á÷¿¡´Â ¿µÇâÀ» ÁÖÁö ¸øÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù.
Àü¸³¼±ºñ´ëÁõȯÀÚ¿¡ ´ëÇÑ ¥á1-¼ö¿ëüÂ÷´ÜÁ¦ »ç¿ë½Ã Ä¡·áÀÇ °á°ú´Â ´Ù¾çÇÏ
°Ô ³ªÅ¸³ª°í ÀÖÀ¸¸ç ÀÌ·¯ÇÑ ÀÌÀ¯ÁßÀÇ ÇÑ ¿äÀÎÀ¸·Î Àü¸³¼±ºñ´ëÁõȯÀÚ¿¡¼­ ¼±Á¾ÀÇ °¢ °³Àκ°
Á¶Á÷ÇÐÀû ´Ù¾ç¼ºÀ» »ý°¢ÇØ º¼ ¼ö ÀÖ´Ù ¥á1,-¼ö¿ëüÂ÷´ÜÁ¦°¡ ÃÖ´ëÈ¿°ú¸¦ ³ªÅ¸
³»´Âµ¥ ¿ä±¸µÇ´Â ±â°£Àº ¾à4ÁÖÁ¤µµÀÎ °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. µû¶ó¼­ ÀúÀÚµéÀº Àü¸³¼±ÀýÁ¦¼úÀÌ
Àü¿¡ 1°³¿ù ÀÌ»ó ¥á1-¼ö¿ëüÂ÷´ÜÁ¦¸¦ Åõ¾àÇÑ È¯ÀÚµéÀ» ´ë»óÀ¸·Î ÇÏ¿© Àü¸³¼±
ÀÇ Á¶Á÷À¯Çü¿¡ µû¸¥¥ál-¼ö¿ëü Â÷´ÜÁ¦ÀÇ Ä¡·áÈ¿°ú¸¦ ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.
#ÃÊ·Ï#
Purpose : Benign prostatic hyperplasia(BPH) describes a hyperplastic process of the
stromal and epithelial elements of the prostate. The proliferative rates of each
compartment in BPH may vary individually and the prostate is topographically not
affected in a uniform way. The proposed mechanism of alphas-blockers in the treatment
of BPH is the decrease of prostatic urethral resistance by relaxing the prostatic smooth
muscle component present in the stroma. The purpose of this study is to search the
effect of alphas-blockers according to histologic compositions in patients with BPH.
Materials and Methods : From January 1994 to June 1997, 74 patients were treated
with alpha1-blockers( 1month) before prostatectomy. Of 74 patients, the
international prostate symptom score(IPSS) was used in 62 patients to evaluate the
severity of voiding difficulties. The clinical response to alpha1-blockers
was based upon change in IPSS during medication period. According to histological
compositions of prostatectomy specimen, the patients were classified into three groups:
predominantly stromal type(20 patients), predominantly glandular type(21 patients) and
mixed type(21 patients).
Results : There were 17 patients In response group and 45 patients in nonresponse
group. The stromal type, glandular type and mixed type were composed of 52.9%, 17.7%
and 29.4% respectively in response group and 24.4%, 40.1% and 35.5% respectively in
nonresponse group. There was not statistical significant differences between clinical
response of the alpha1-blockers and histologic compositions in patients
with BPH(p>0.05).
Conclusions : Although stromal type was predominant in response group and glandular
type was predominant in nonresponse group, the relationship between the effects of
alpha1-blockers and histologic compositions in patients with BPH was not
statistically significant. Further evaluation will be necessary to assess the association
between effects of alpha1-blockers and histologic difference of prostate in
patients with BPH.
(Korean J Urol 1998; 39: 783¡­7)

Å°¿öµå

Benign prostatic hyperplasia; Alpha1-blockers; Epithelium;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS